Masahito Kawabori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masahito Kawabori has a total of 253 co-authors. Here are the top co-authors by number of shared publications:
Kiyohiro Houkin
Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan
18 shared publicationsMiki Fujimura
Department of Neurosurgery, Hokkaido University Graduate School of Medicine
17 shared publications- Kiyohiro Houkin
Department of Neurosurgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan
8 shared publications - Miki Fujimura
Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan
7 shared publications - Naoki Nakayama
Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan
7 shared publications Yoshinobu Iwasaki
Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan
7 shared publications
Latest Publications
- Open Access
- 31 December 2026
- Published by Japan Neurosurgical Society in NMC Case Report Journal
- Vol. 13, 147-151
An Ectopic Tentorial Schwannoma Mimicking Tentorial Meningioma: A Case Report and Literature Review
Intracranial schwannomas account for approximately 8% of all primary brain tumors, and the majority arise in the cerebellopontine angle. Ectopic schwannomas that originate from non-cranial nerve sites, such as the dura mater or brain parenchyma, are rare, representing less than 1% of all intracranial schwannomas. These lesions often mimic meningiomas on neuroimaging, making preoperative diagnosis challenging. A woman in her 50s was referred to our department after a brain check-up incidentally revealed a mass lesion extending both above and below the tentorium. Neurological examination was unremarkable. Magnetic resonance imaging demonstrated a well-defined, heterogeneously enhancing extra-axial mass widely attached to the tentorium, suggestive of meningioma. The lesion was completely resected via a suboccipital approach. Histopathological examination revealed spindle-shaped tumor cells with palisading nuclei, positive for S-100 protein and negative for epithelial membrane antigen, confirming the diagnosis of schwannoma. The MIB-1 (Ki-67) labeling index was below 5%, consistent with a benign lesion. Postoperative magnetic resonance imaging confirmed total resection, and the patient's postoperative course was uneventful. No recurrence was observed during a 7-month follow-up period. Tentorial ectopic schwannoma is an extremely rare entity that can closely resemble meningioma both radiologically and intraoperatively. Awareness of this entity is important when evaluating tentorial extra-axial tumors. Although the clinical course is generally favorable following complete resection, careful preoperative evaluation is essential for accurate diagnosis and appropriate management.
- 31 December 2026
- Published by Japan Neurosurgical Society in NMC Case Report Journal
- Vol. 13, 147-151
Open AccessAn Ectopic Tentorial Schwannoma Mimicking Tentorial Meningioma: A Case Report and Literature Review
Intracranial schwannomas account for approximately 8% of all primary brain tumors, and the majority arise in the cerebellopontine angle. Ectopic schwannomas that originate from non-cranial nerve sites, such as the dura mater or brain parenchyma, are rare, representing less than 1% of all intracranial schwannomas. These lesions often mimic meningiomas on neuroimaging, making preoperative diagnosis challenging. A woman in her 50s was referred to our department after a brain check-up incidentally revealed a mass lesion extending both above and below the tentorium. Neurological examination was unremarkable. Magnetic resonance imaging demonstrated a well-defined, heterogeneously enhancing extra-axial mass widely attached to the tentorium, suggestive of meningioma. The lesion was completely resected via a suboccipital approach. Histopathological examination revealed spindle-shaped tumor cells with palisading nuclei, positive for S-100 protein and negative for epithelial membrane antigen, confirming the diagnosis of schwannoma. The MIB-1 (Ki-67) labeling index was below 5%, consistent with a benign lesion. Postoperative magnetic resonance imaging confirmed total resection, and the patient's postoperative course was uneventful. No recurrence was observed during a 7-month follow-up period. Tentorial ectopic schwannoma is an extremely rare entity that can closely resemble meningioma both radiologically and intraoperatively. Awareness of this entity is important when evaluating tentorial extra-axial tumors. Although the clinical course is generally favorable following complete resection, careful preoperative evaluation is essential for accurate diagnosis and appropriate management.
- Open Access
- 2 November 2026
- Published by Springer Nature in Stem Cell Research & Therapy
Intra-arterial delivery of MSC-derived extracellular vesicles in the post-thrombectomy setting attenuates ischemic brain injury
Background: Ischemic stroke remains a major global cause of mortality and disability. Although the development of recombinant tissue plasminogen activator (rt-PA) and endovascular thrombectomy has improved clinical outcomes, nearly half of patients still experience unfavorable outcomes, underscoring the need for innovative therapeutic strategies. In the present study, we investigated intra-arterially administered human amniotic mesenchymal stromal cells (MSCs)–derived extracellular vesicles (EVs) immediately after ischemic stroke, mimicking successful recanalization following thrombectomy, and evaluated their neuroprotective effects. Methods: EVs were isolated from the conditioned media of amnion-derived MSCs. Middle cerebral artery occlusion was induced in 8-week-old Sprague–Dawley rats using an intraluminal filament model, followed by complete recanalization 2 h after ischemia. A total of 5 × 10 9 EV particles suspended in 500 µL of phosphate-buffered saline (PBS), or PBS alone as a control, were administered intra-arterially through the same artery immediately after reperfusion. Neurological function was assessed for up to 7 days after MCAO, followed by histological analyses of inflammatory responses and neutrophil extracellular traps (NETs) formation. Biodistribution of EVs was evaluated using positron emission tomography/computed tomography (PET/CT) imaging with 64 Cu-labeled EVs. Blood–brain barrier (BBB) integrity was assessed using Evans blue extravasation, and quantitative proteomic analyses were performed using both brain capillary–enriched fractions and whole-brain tissue to characterize changes in the host brain microenvironment. Results: The EV group demonstrated significantly improved neurological recovery and a lower mortality rate compared with controls, whereas body weight recovery and infarct volume did not reach statistical significance. Histological analyses revealed significant reductions in inflammation (Iba1, CD68) and apoptosis (TUNEL) in the EV-treated group. EV group further demonstrated preserved BBB function, and suppressed intraparenchymal NETs formation. Biodistribution analysis showed that the majority of EVs accumulated in the liver as early as 1 h after administration, although signals were also detected in the ipsilateral brain hemisphere. Proteomic analyses demonstrated upregulation of endopeptidase inhibition cascades and mitochondrial activities, suggesting a mechanistic link to the inhibition of NETs formation, and preservation of cell functions respectively. Conclusions: MSC-derived EVs were successfully delivered to the brain via intra-arterial administration and attenuated ischemic brain injury, at least in part, through preservation of BBB integrity and inhibition of NET formation.
- 2 November 2026
- Published by Springer Nature in Stem Cell Research & Therapy
Open AccessIntra-arterial delivery of MSC-derived extracellular vesicles in the post-thrombectomy setting attenuates ischemic brain injury
Background: Ischemic stroke remains a major global cause of mortality and disability. Although the development of recombinant tissue plasminogen activator (rt-PA) and endovascular thrombectomy has improved clinical outcomes, nearly half of patients still experience unfavorable outcomes, underscoring the need for innovative therapeutic strategies. In the present study, we investigated intra-arterially administered human amniotic mesenchymal stromal cells (MSCs)–derived extracellular vesicles (EVs) immediately after ischemic stroke, mimicking successful recanalization following thrombectomy, and evaluated their neuroprotective effects. Methods: EVs were isolated from the conditioned media of amnion-derived MSCs. Middle cerebral artery occlusion was induced in 8-week-old Sprague–Dawley rats using an intraluminal filament model, followed by complete recanalization 2 h after ischemia. A total of 5 × 10 9 EV particles suspended in 500 µL of phosphate-buffered saline (PBS), or PBS alone as a control, were administered intra-arterially through the same artery immediately after reperfusion. Neurological function was assessed for up to 7 days after MCAO, followed by histological analyses of inflammatory responses and neutrophil extracellular traps (NETs) formation. Biodistribution of EVs was evaluated using positron emission tomography/computed tomography (PET/CT) imaging with 64 Cu-labeled EVs. Blood–brain barrier (BBB) integrity was assessed using Evans blue extravasation, and quantitative proteomic analyses were performed using both brain capillary–enriched fractions and whole-brain tissue to characterize changes in the host brain microenvironment. Results: The EV group demonstrated significantly improved neurological recovery and a lower mortality rate compared with controls, whereas body weight recovery and infarct volume did not reach statistical significance. Histological analyses revealed significant reductions in inflammation (Iba1, CD68) and apoptosis (TUNEL) in the EV-treated group. EV group further demonstrated preserved BBB function, and suppressed intraparenchymal NETs formation. Biodistribution analysis showed that the majority of EVs accumulated in the liver as early as 1 h after administration, although signals were also detected in the ipsilateral brain hemisphere. Proteomic analyses demonstrated upregulation of endopeptidase inhibition cascades and mitochondrial activities, suggesting a mechanistic link to the inhibition of NETs formation, and preservation of cell functions respectively. Conclusions: MSC-derived EVs were successfully delivered to the brain via intra-arterial administration and attenuated ischemic brain injury, at least in part, through preservation of BBB integrity and inhibition of NET formation.
- Open Access
- 10 August 2026
- Published by Elsevier in Experimental Neurology
- Vol. 406, 115954
Enhanced therapeutic effect of intracavitary mesenchymal stromal cell administration with alginate scaffold in acute intracerebral hemorrhage model rat after hematoma aspiration
- 10 August 2026
- Published by Elsevier in Experimental Neurology
- Vol. 406, 115954
Open AccessEnhanced therapeutic effect of intracavitary mesenchymal stromal cell administration with alginate scaffold in acute intracerebral hemorrhage model rat after hematoma aspiration
- Open Access
- 12 May 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Serial brain FDG-PET and IMZ-SPECT following intracerebral MSC transplantation in patients with subacute ischemic stroke
Ischemic stroke is a leading cause of mortality and long-term neurological disability worldwide, and cell-based therapies represent a promising approach. A
- 12 May 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Open AccessSerial brain FDG-PET and IMZ-SPECT following intracerebral MSC transplantation in patients with subacute ischemic stroke
Ischemic stroke is a leading cause of mortality and long-term neurological disability worldwide, and cell-based therapies represent a promising approach. A
- Open Access
- 24 April 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Phase-dependent efficacy of intravenous amniotic mesenchymal stem cells in a rat spinal cord injury model
Background: Spinal cord injury results in profound neurological disability driven initially by primary mechanical damage and subsequently by secondary injury processes characterized by progressive neuroinflammation. Intravenous administration of human amniotic mesenchymal stem cells (MSC) has emerged as a promising therapeutic approach; however, the optimal timing of administration and its relationship to dynamic immune responses remain unclear. Methods: A rat contusion model of spinal cord injury was used to evaluate the effects of intravenous MSC administration at three post-injury time points: days 1, 3, and 7. Functional and histological assessments were performed for each group. Systemic inflammatory responses were evaluated through blood analysis of neutrophil and macrophage counts, systemic inflammation index (SII), and plasma proteomics. Local immune responses were assessed by quantifying infiltrating immune cells within the injured spinal cord. Results: The most substantial improvement in locomotor function was observed in the day-1 treatment group, followed by the day-7 group, whereas the day-3 group showed minimal benefit. The day-3 group also demonstrated a trend toward greater lesion length and increased macrophage infiltration 28 days after injury. MSC administration reduced SII in the day-1 and day-7 groups but not in the day-3 group, which instead showed an increased systemic inflammatory response. Analysis of spinal cord tissue demonstrated that MSC treatment on day-1 effectively reduced neutrophil infiltration, which peaks at this time point, while day-7 administration reduced macrophage infiltration during its peak phase. In contrast, MSC administration on day-3 failed to attenuate either neutrophil or macrophage accumulation. Plasma proteomic profiling revealed enhanced complement and coagulation pathway activation specifically on day-3. Conclusions: The therapeutic efficacy of intravenously administered MSC is highly dependent on the timing of intervention. Optimal benefit is achieved when treatment coincides with peak activation of a dominant target immune cell population and avoids the peak of complement and coagulation signaling. These findings support a phase-matched therapeutic strategy to maximize MSC effectiveness following spinal cord injury.
- 24 April 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Open AccessPhase-dependent efficacy of intravenous amniotic mesenchymal stem cells in a rat spinal cord injury model
Background: Spinal cord injury results in profound neurological disability driven initially by primary mechanical damage and subsequently by secondary injury processes characterized by progressive neuroinflammation. Intravenous administration of human amniotic mesenchymal stem cells (MSC) has emerged as a promising therapeutic approach; however, the optimal timing of administration and its relationship to dynamic immune responses remain unclear. Methods: A rat contusion model of spinal cord injury was used to evaluate the effects of intravenous MSC administration at three post-injury time points: days 1, 3, and 7. Functional and histological assessments were performed for each group. Systemic inflammatory responses were evaluated through blood analysis of neutrophil and macrophage counts, systemic inflammation index (SII), and plasma proteomics. Local immune responses were assessed by quantifying infiltrating immune cells within the injured spinal cord. Results: The most substantial improvement in locomotor function was observed in the day-1 treatment group, followed by the day-7 group, whereas the day-3 group showed minimal benefit. The day-3 group also demonstrated a trend toward greater lesion length and increased macrophage infiltration 28 days after injury. MSC administration reduced SII in the day-1 and day-7 groups but not in the day-3 group, which instead showed an increased systemic inflammatory response. Analysis of spinal cord tissue demonstrated that MSC treatment on day-1 effectively reduced neutrophil infiltration, which peaks at this time point, while day-7 administration reduced macrophage infiltration during its peak phase. In contrast, MSC administration on day-3 failed to attenuate either neutrophil or macrophage accumulation. Plasma proteomic profiling revealed enhanced complement and coagulation pathway activation specifically on day-3. Conclusions: The therapeutic efficacy of intravenously administered MSC is highly dependent on the timing of intervention. Optimal benefit is achieved when treatment coincides with peak activation of a dominant target immune cell population and avoids the peak of complement and coagulation signaling. These findings support a phase-matched therapeutic strategy to maximize MSC effectiveness following spinal cord injury.
- Open Access
- 15 February 2026
- Published by Japan Neurosurgical Society in Neurologia medico-chirurgica
- Vol. 66 (2) , 90-98
Clazosentan Affects Temporal Profile of Endothelin-A Expression in Macro- and Microcirculation after Subarachnoid Hemorrhage
Subarachnoid hemorrhage is a life-threatening cerebrovascular event, and cerebral vasospasm remains a major cause of poor neurological outcomes. Clazosentan, an endothelin-A receptor antagonist, has been recently approved in Japan to reduce post-subarachnoid hemorrhage vasospasm; however, recurrent vasospasm after cessation of therapy has occasionally been reported, which underlying mechanisms remain unclear. Moreover, endothelin-A receptor is also expressed on pericytes; however, the effects of clazosentan on microvascular endothelin-A receptor remain unexplored. In this study, we employed a rat subarachnoid hemorrhage model to investigate the temporal dynamics of vasospasm and endothelin-A receptor expression in both large arteries and microvessels, and to evaluate the effects of clazosentan administration. Sprague-Dawley rats were assigned to naïve controls, subarachnoid hemorrhage with saline, or subarachnoid hemorrhage with continuous clazosentan administration for 7 days via osmotic pumps. Vasospasm was assessed by arterial wall thickness, and endothelin-A receptor expression was quantified using immunohistochemistry and immunofluorescence, including staining with α-SMA, CD31, and PDGF-β. Clazosentan significantly attenuated vasospasm in the middle and anterior cerebral arteries, and recurrent vasospasm was observed 3 days after cessation of clazosentan, coinciding with sustained upregulation of endothelin-A receptor in these vessels. In microvessels, pericyte density transiently decreased, peaking at a nadir on day 3 post-subarachnoid hemorrhage, while endothelin-A receptor expression on pericytes was highest at the same time point, and further elevated by clazosentan treatment. These findings indicate that clazosentan induces endothelin-A receptor upregulation in both macro- and microcirculation, potentially contributing to recurrent vasospasm after treatment, and highlight the critical role of pericytes in post-subarachnoid hemorrhage vascular regulation.
- 15 February 2026
- Published by Japan Neurosurgical Society in Neurologia medico-chirurgica
- Vol. 66 (2) , 90-98
Open AccessClazosentan Affects Temporal Profile of Endothelin-A Expression in Macro- and Microcirculation after Subarachnoid Hemorrhage
Subarachnoid hemorrhage is a life-threatening cerebrovascular event, and cerebral vasospasm remains a major cause of poor neurological outcomes. Clazosentan, an endothelin-A receptor antagonist, has been recently approved in Japan to reduce post-subarachnoid hemorrhage vasospasm; however, recurrent vasospasm after cessation of therapy has occasionally been reported, which underlying mechanisms remain unclear. Moreover, endothelin-A receptor is also expressed on pericytes; however, the effects of clazosentan on microvascular endothelin-A receptor remain unexplored. In this study, we employed a rat subarachnoid hemorrhage model to investigate the temporal dynamics of vasospasm and endothelin-A receptor expression in both large arteries and microvessels, and to evaluate the effects of clazosentan administration. Sprague-Dawley rats were assigned to naïve controls, subarachnoid hemorrhage with saline, or subarachnoid hemorrhage with continuous clazosentan administration for 7 days via osmotic pumps. Vasospasm was assessed by arterial wall thickness, and endothelin-A receptor expression was quantified using immunohistochemistry and immunofluorescence, including staining with α-SMA, CD31, and PDGF-β. Clazosentan significantly attenuated vasospasm in the middle and anterior cerebral arteries, and recurrent vasospasm was observed 3 days after cessation of clazosentan, coinciding with sustained upregulation of endothelin-A receptor in these vessels. In microvessels, pericyte density transiently decreased, peaking at a nadir on day 3 post-subarachnoid hemorrhage, while endothelin-A receptor expression on pericytes was highest at the same time point, and further elevated by clazosentan treatment. These findings indicate that clazosentan induces endothelin-A receptor upregulation in both macro- and microcirculation, potentially contributing to recurrent vasospasm after treatment, and highlight the critical role of pericytes in post-subarachnoid hemorrhage vascular regulation.
- Open Access
- 18 November 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 646
Reverse translational research of transient magnetic resonance imaging hyperintensity following intracranial stem cell therapy
Background: Neurological disorders, such as stroke and traumatic brain injury are the most significant global health challenges, leading to long-term physical and cognitive impairments. Cell transplantation therapy holds substantial promise for facilitating recovery, with numerous clinical trials currently underway. Intracerebral stem cell infusion offers the advantage of directly delivering a sufficient number of stem cells to the targeted area. Both our team and other researchers have observed a notable phenomenon following intracerebral stem cell therapy in clinical trials, wherein transient edema, as detected by Fluid Attenuated Inversion Recovery (FLAIR) magnetic resonance (MR) imaging, can be monitored between one and two weeks post-transplantation, with a subsequent resolution occurring approximately one month later. Notably, patient recovery appears to accelerate during the period of elevated FLAIR signals. However, the precise mechanisms underlying this distinctive phenomenon remain poorly understood. Therefore, this reverse translational research employs proteomics and histological analysis to investigate the mechanisms driving this phenomenon, thereby enhancing our understanding of stem cell therapy. Methods: Bone marrow-derived mesenchymal stem cells (BMSCs) were isolated from Sprague-Dawley (SD) rats, with passage 3 cells utilized for subsequent experiments. A total of one million cells, suspended in 10 µL of phosphate-buffered saline, were intracerebrally transplanted into the striatum of SD rats. Serial magnetic resonance imaging (FLAIR) scans were performed up to three weeks post-transplantation. Brain tissues were collected from the pre-signal (1 week post-transplantation), signal (2 weeks post-transplantation), and post-signal (3 weeks post-transplantation) groups for proteomic analysis, network analysis, and immunofluorescence imaging. Results: Consistent with clinical trials, transient FLAIR hyperintense signals were not detected until approximately two weeks post-intracranial stem cell therapy. These signals emerged around week two and diminished by week three. Proteomic analysis of brain specimens from the pre-signal and signal groups identified 231 differentially expressed proteins, which were primarily involved in vesicle-mediated transport, synaptic remodeling, and cellular communication. Glial fibrillary acidic protein (GFAP), Aquaporin-4 (AQP4), and Apolipoprotein E (APOE) were identified as key hub proteins. Immunofluorescence studies further confirmed that expression levels of GFAP, AQP4, and APOE increased around two weeks post-transplantation and significantly decreased by week three, coinciding with the resolution of the FLAIR signal. Conclusions: Our findings suggest that the transient FLAIR hyperintensity observed following intracerebral stem cell therapy is primarily attributed to transient glial cell activation, resulting in increased AQP4 expression and transient brain water influx. Additional mechanisms, including vesicle-mediated transport, secretion, synaptic activity, and lipid signaling, also contribute to the transient FLAIR hyperintensity signals and may play a role in the manifestation of clinical symptoms.
- 18 November 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 646
Open AccessReverse translational research of transient magnetic resonance imaging hyperintensity following intracranial stem cell therapy
Background: Neurological disorders, such as stroke and traumatic brain injury are the most significant global health challenges, leading to long-term physical and cognitive impairments. Cell transplantation therapy holds substantial promise for facilitating recovery, with numerous clinical trials currently underway. Intracerebral stem cell infusion offers the advantage of directly delivering a sufficient number of stem cells to the targeted area. Both our team and other researchers have observed a notable phenomenon following intracerebral stem cell therapy in clinical trials, wherein transient edema, as detected by Fluid Attenuated Inversion Recovery (FLAIR) magnetic resonance (MR) imaging, can be monitored between one and two weeks post-transplantation, with a subsequent resolution occurring approximately one month later. Notably, patient recovery appears to accelerate during the period of elevated FLAIR signals. However, the precise mechanisms underlying this distinctive phenomenon remain poorly understood. Therefore, this reverse translational research employs proteomics and histological analysis to investigate the mechanisms driving this phenomenon, thereby enhancing our understanding of stem cell therapy. Methods: Bone marrow-derived mesenchymal stem cells (BMSCs) were isolated from Sprague-Dawley (SD) rats, with passage 3 cells utilized for subsequent experiments. A total of one million cells, suspended in 10 µL of phosphate-buffered saline, were intracerebrally transplanted into the striatum of SD rats. Serial magnetic resonance imaging (FLAIR) scans were performed up to three weeks post-transplantation. Brain tissues were collected from the pre-signal (1 week post-transplantation), signal (2 weeks post-transplantation), and post-signal (3 weeks post-transplantation) groups for proteomic analysis, network analysis, and immunofluorescence imaging. Results: Consistent with clinical trials, transient FLAIR hyperintense signals were not detected until approximately two weeks post-intracranial stem cell therapy. These signals emerged around week two and diminished by week three. Proteomic analysis of brain specimens from the pre-signal and signal groups identified 231 differentially expressed proteins, which were primarily involved in vesicle-mediated transport, synaptic remodeling, and cellular communication. Glial fibrillary acidic protein (GFAP), Aquaporin-4 (AQP4), and Apolipoprotein E (APOE) were identified as key hub proteins. Immunofluorescence studies further confirmed that expression levels of GFAP, AQP4, and APOE increased around two weeks post-transplantation and significantly decreased by week three, coinciding with the resolution of the FLAIR signal. Conclusions: Our findings suggest that the transient FLAIR hyperintensity observed following intracerebral stem cell therapy is primarily attributed to transient glial cell activation, resulting in increased AQP4 expression and transient brain water influx. Additional mechanisms, including vesicle-mediated transport, secretion, synaptic activity, and lipid signaling, also contribute to the transient FLAIR hyperintensity signals and may play a role in the manifestation of clinical symptoms.
- Open Access
- 15 August 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1606606
Intraventricular continuous BDNF administration ameliorates neuroinflammation and enhances neurogenesis against rodent intracerebral hemorrhage model
Objective: Brain-derived neurotrophic factor (BDNF) is a pivotal growth factor for neuronal survival; however, its precise role following intracerebral hemorrhage (ICH) remains poorly understood. This study sought to investigate whether intraventricular administration of BDNF could enhance neurogenesis and ameliorate neuroinflammation, resulting in improvement of neurological outcomes in a rat ICH model.Methods: Male Sprague–Dawley rats were utilized to create an acute ICH model by collagenase infusion into the internal capsule. An intraventricular minipump was subcutaneously implanted, with the catheter tip inserted into the contralateral ventricle to deliver BDNF for 7 consecutive days. The rats were assigned to one of three experimental groups; the BDNF group, the anti-BDNF antibody group, and the sham group. Functional assessment was conducted up to 14 days post-ICH, and immunohistochemical analysis was performed to evaluate neurogenesis, apoptosis, and neuroinflammation in the perihematomal area and the subventricular zone (SVZ).Results: Brain-derived neurotrophic factor treatment significantly increased the proliferation of neural stem cells in the perihematomal region. It also reduced the neuroinflammation 14 days post-ICH. Additionally, BDNF treatment demonstrated a favorable neurological function at 14 days post-ICH.Conclusion: Intraventricular administration of BDNF demonstrated favorable recovery after ICH by reducing inflammation and enhancing neurogenesis.
- 15 August 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1606606
Open AccessIntraventricular continuous BDNF administration ameliorates neuroinflammation and enhances neurogenesis against rodent intracerebral hemorrhage model
Objective: Brain-derived neurotrophic factor (BDNF) is a pivotal growth factor for neuronal survival; however, its precise role following intracerebral hemorrhage (ICH) remains poorly understood. This study sought to investigate whether intraventricular administration of BDNF could enhance neurogenesis and ameliorate neuroinflammation, resulting in improvement of neurological outcomes in a rat ICH model.Methods: Male Sprague–Dawley rats were utilized to create an acute ICH model by collagenase infusion into the internal capsule. An intraventricular minipump was subcutaneously implanted, with the catheter tip inserted into the contralateral ventricle to deliver BDNF for 7 consecutive days. The rats were assigned to one of three experimental groups; the BDNF group, the anti-BDNF antibody group, and the sham group. Functional assessment was conducted up to 14 days post-ICH, and immunohistochemical analysis was performed to evaluate neurogenesis, apoptosis, and neuroinflammation in the perihematomal area and the subventricular zone (SVZ).Results: Brain-derived neurotrophic factor treatment significantly increased the proliferation of neural stem cells in the perihematomal region. It also reduced the neuroinflammation 14 days post-ICH. Additionally, BDNF treatment demonstrated a favorable neurological function at 14 days post-ICH.Conclusion: Intraventricular administration of BDNF demonstrated favorable recovery after ICH by reducing inflammation and enhancing neurogenesis.
- Open Access
- 31 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7405
Intra-Arterial Administration of Stem Cells and Exosomes for Central Nervous System Disease
Central nervous system (CNS) disorders present significant therapeutic challenges due to the limited regenerative capacity of neural tissues, resulting in long-term disability for many patients. Consequently, the development of novel therapeutic strategies is urgently warranted. Stem cell therapies show considerable potential for mitigating brain damage and restoring neural connectivity, owing to their multifaceted properties, including anti-apoptotic, anti-inflammatory, neurogenic, and vasculogenic effects. Recent research has also identified exosomes—small vesicles enclosed by a lipid bilayer, secreted by stem cells—as a key mechanism underlying the therapeutic effects of stem cell therapies, and given their enhanced stability and superior blood–brain barrier permeability compared to the stem cells themselves, exosomes have emerged as a promising alternative treatment for CNS disorders. A key challenge in the application of both stem cell and exosome-based therapies for CNS diseases is the method of delivery. Currently, several routes are being investigated, including intracerebral, intrathecal, intravenous, intranasal, and intra-arterial administration. Intracerebral injection can deliver a substantial quantity of stem cells directly to the brain, but it carries the potential risk of inducing additional brain injury. Conversely, intravenous transplantation is minimally invasive but results in limited delivery of cells and exosomes to the brain, which may compromise the therapeutic efficacy. With advancements in catheter technology, intra-arterial administration of stem cells and exosomes has garnered increasing attention as a promising delivery strategy. This approach offers the advantage of delivering a significant number of stem cells and exosomes to the brain while minimizing the risk of additional brain damage. However, the investigation into the therapeutic potential of intra-arterial transplantation for CNS injury is still in its early stages. In this comprehensive review, we aim to summarize both basic and clinical research exploring the intra-arterial administration of stem cells and exosomes for the treatment of CNS diseases. Additionally, we will elucidate the underlying therapeutic mechanisms and provide insights into the future potential of this approach.
- 31 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7405
Open AccessIntra-Arterial Administration of Stem Cells and Exosomes for Central Nervous System Disease
Central nervous system (CNS) disorders present significant therapeutic challenges due to the limited regenerative capacity of neural tissues, resulting in long-term disability for many patients. Consequently, the development of novel therapeutic strategies is urgently warranted. Stem cell therapies show considerable potential for mitigating brain damage and restoring neural connectivity, owing to their multifaceted properties, including anti-apoptotic, anti-inflammatory, neurogenic, and vasculogenic effects. Recent research has also identified exosomes—small vesicles enclosed by a lipid bilayer, secreted by stem cells—as a key mechanism underlying the therapeutic effects of stem cell therapies, and given their enhanced stability and superior blood–brain barrier permeability compared to the stem cells themselves, exosomes have emerged as a promising alternative treatment for CNS disorders. A key challenge in the application of both stem cell and exosome-based therapies for CNS diseases is the method of delivery. Currently, several routes are being investigated, including intracerebral, intrathecal, intravenous, intranasal, and intra-arterial administration. Intracerebral injection can deliver a substantial quantity of stem cells directly to the brain, but it carries the potential risk of inducing additional brain injury. Conversely, intravenous transplantation is minimally invasive but results in limited delivery of cells and exosomes to the brain, which may compromise the therapeutic efficacy. With advancements in catheter technology, intra-arterial administration of stem cells and exosomes has garnered increasing attention as a promising delivery strategy. This approach offers the advantage of delivering a significant number of stem cells and exosomes to the brain while minimizing the risk of additional brain damage. However, the investigation into the therapeutic potential of intra-arterial transplantation for CNS injury is still in its early stages. In this comprehensive review, we aim to summarize both basic and clinical research exploring the intra-arterial administration of stem cells and exosomes for the treatment of CNS diseases. Additionally, we will elucidate the underlying therapeutic mechanisms and provide insights into the future potential of this approach.
- Open Access
- 23 April 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-10
Human platelet lysate produced from leukoreduction filter contents enables sufficient MSC growth
Background: Stem cell therapy holds significant potential for promoting recovery, with numerous products currently under development. Blood-derived supplements are often essential for successful stem cell expansion, with fetal bovine serum (FBS) being the most commonly used supplement. However, FBS has drawbacks, including the risk of immune responses, ethical concerns about animal welfare, and potential zoonotic infections. Human platelet lysate (hPL), derived from lysed platelets, contains various growth factors and has been proposed as an alternative to FBS. However, obtaining sufficient human platelets for clinical use remains challenging. Leukoreduction filters, used during blood transfusion manufacturing to remove leukocytes, also retain significant amounts of platelets and plasma. This study investigates the feasibility and efficacy of filter-derived hPL (f-hPL) for mesenchymal stem cell (MSC) expansion. Methods: Leukoreduction filters were collected after their use in the manufacturing of whole blood transfusion products. Each filter was reverse-perfused with saline to extract residual blood contents. Platelets (f-platelet) and supernatant were separated by multiple centrifugation steps. f-Platelet were lysed with varying concentrations of fresh frozen plasma (FFP) to determine the optimal protein concentration for the lysate solution. Then, plasma left in the leukoreduction filters were used to generate lysate solution (f-plasma) at optimal protein concentration. f-Platelet (1.1 × 109/mL) and f-plasma (27 mg/mL protein) were combined in a freezing bag and subjected to three freeze-thaw cycles to produce f-hPL. Both small- and large-scale f-hPL were manufactured, and MSCs expansion and quality assessments were perfomed to evaluate the efficacy of f-hPL. Results: A total of 3.5 ± 0.6 × 1010 f-platelets were obtained from a single leukoreduction filter, yielding a collection efficiency of 37.1 ± 5.3%. The optimal protein concentration of lysate solution for cell expansion was > 27 mg/mL. Subsequently, six leukoreduction filters used to produce enough f-platelet and p-plasma for 100 mL of f-hPL. MSCs cultured in medium supplemented with 10% f-hPL demonstrated superior expansion, with cell proliferation rates 20% higher than those observed with commercial hPL and 300% higher than those cultured with FBS. The expanded MSCs met the International Society for Cell & Gene Therapy criteria for cell surface markers and differentiation potential. MSCs expanded with f-hPL expressed similar to or higher amounts of hepatocyte growth factor compared with those cultured with FBS and human AB serum. Furthermore, f-hPL significantly enhanced cell proliferation up to P12 and effectively prevented cell senescence. Conclusion: f-hPL derived from leukoreduction filters demonstrated strong capacity for MSCs expansion. The use of discarded blood materials for regenerative medicine represents a sustainable and efficient approach, with significant therapeutic potential.
- 23 April 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-10
Open AccessHuman platelet lysate produced from leukoreduction filter contents enables sufficient MSC growth
Background: Stem cell therapy holds significant potential for promoting recovery, with numerous products currently under development. Blood-derived supplements are often essential for successful stem cell expansion, with fetal bovine serum (FBS) being the most commonly used supplement. However, FBS has drawbacks, including the risk of immune responses, ethical concerns about animal welfare, and potential zoonotic infections. Human platelet lysate (hPL), derived from lysed platelets, contains various growth factors and has been proposed as an alternative to FBS. However, obtaining sufficient human platelets for clinical use remains challenging. Leukoreduction filters, used during blood transfusion manufacturing to remove leukocytes, also retain significant amounts of platelets and plasma. This study investigates the feasibility and efficacy of filter-derived hPL (f-hPL) for mesenchymal stem cell (MSC) expansion. Methods: Leukoreduction filters were collected after their use in the manufacturing of whole blood transfusion products. Each filter was reverse-perfused with saline to extract residual blood contents. Platelets (f-platelet) and supernatant were separated by multiple centrifugation steps. f-Platelet were lysed with varying concentrations of fresh frozen plasma (FFP) to determine the optimal protein concentration for the lysate solution. Then, plasma left in the leukoreduction filters were used to generate lysate solution (f-plasma) at optimal protein concentration. f-Platelet (1.1 × 109/mL) and f-plasma (27 mg/mL protein) were combined in a freezing bag and subjected to three freeze-thaw cycles to produce f-hPL. Both small- and large-scale f-hPL were manufactured, and MSCs expansion and quality assessments were perfomed to evaluate the efficacy of f-hPL. Results: A total of 3.5 ± 0.6 × 1010 f-platelets were obtained from a single leukoreduction filter, yielding a collection efficiency of 37.1 ± 5.3%. The optimal protein concentration of lysate solution for cell expansion was > 27 mg/mL. Subsequently, six leukoreduction filters used to produce enough f-platelet and p-plasma for 100 mL of f-hPL. MSCs cultured in medium supplemented with 10% f-hPL demonstrated superior expansion, with cell proliferation rates 20% higher than those observed with commercial hPL and 300% higher than those cultured with FBS. The expanded MSCs met the International Society for Cell & Gene Therapy criteria for cell surface markers and differentiation potential. MSCs expanded with f-hPL expressed similar to or higher amounts of hepatocyte growth factor compared with those cultured with FBS and human AB serum. Furthermore, f-hPL significantly enhanced cell proliferation up to P12 and effectively prevented cell senescence. Conclusion: f-hPL derived from leukoreduction filters demonstrated strong capacity for MSCs expansion. The use of discarded blood materials for regenerative medicine represents a sustainable and efficient approach, with significant therapeutic potential.